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Human cytomegalovirus (HCMV) has been closely associated with the human race 
across evolutionary time. HCMV co-infection is nearly universal in human immunode-
ficiency virus-1 (HIV-1)-infected individuals and remains an important cofactor in HIV-1 
disease progression even in the era of effective antiretroviral treatment. HCMV infection 
has been shown to have a broad and potent influence on the human immune system 
and has been linked with the discovery and characterization of adaptive natural killer (NK) 
cells. Distinct NK-cell subsets, predominately expressing the activating receptor NKG2C 
and the marker of terminal differentiation CD57, expand in response to HCMV. These 
NK-cell populations engaged in the long-lasting interaction with HCMV, in addition to 
characteristic but variable expression of surface receptors, exhibit reduced expression of 
signaling proteins and transcription factors expressed by canonical NK cells. Broad epi-
genetic modifications drive the emergence and persistence of HCMV-adapted NK cells 
that have distinct functional characteristics. NKG2C+ NK-cell expansions have been 
observed in HIV-1 infected patients and other acute and chronic viral infections being 
systematically associated with HCMV seropositivity. The latter is potentially an important 
confounding variable in studies focused on the cellular NK-cell receptor repertoire and 
functional capacity. Here, focusing on HIV-1 infection we review the evidence in favor of 
“adaptive” changes likely induced by HCMV co-infection in NK-cell subsets. We highlight 
a number of key questions and how insights into the adaptive behavior of NK cells will 
inform new strategies exploiting their unique properties in the fight against HIV-1.
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inTRODUCTiOn
Natural killer (NK) cells are a diverse group of innate lymphocytes residing at the crossroads of innate 
and adaptive immunity (1). Their remarkable effector agility is achieved via expression of a wide 
array of receptors and integration of signals that are finely attuned to ensure self-tolerance, while per-
mitting effective responses against viral assaults and tumor transformation. In addition to important 
immunoregulatory functions (2, 3), a number of murine studies support that NK cells can acquire 
immunological memory similarly to B and T cells (4–7). While antigen-specific NK responses have 
been documented in mice and more recently in primates (8), clear evidence for NK-cell memory 
2Peppa HIV-1/HCMV Co-Infection and NK Cells
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1322
in humans is lacking. The NK-cell compartment in humans 
displays phenotypic and functional heterogeneity encompassing 
populations at various stages of maturation with distinct receptor 
combinations (9–11). In recent years, it has become apparent that 
variegated expression of inhibitory and activating receptors at the 
single cell level leads to a more diverse NK-cell repertoire than 
previously envisaged. Cytometry by time-of-flight has enabled 
us to profile the healthy human NK-cell repertoire, uncovering 
between 6,000 and 30,000 unique NK-cell subsets per individual 
(12). This observed diversity is generated by a combination of 
factors including genetic contributions (13, 14), along with dif-
ferentiation in reprogramming in response to local tissue milieu 
(15) and infections/environmental factors (12). The substantial 
influence of environmental factors is supported by twin studies 
demonstrating that non-heritable factors exert a more profound 
and cumulative influence compared to heritable traits (16, 17). 
One such factor is human cytomegalovirus (HCMV), a wide-
spread β-herpesvirus with a prevalence ranging from 40 to 100% 
depending on age, socioeconomic factors, and geographical 
region (18). In immunocompetent hosts, HCMV infection is usu-
ally subclinical leading to latency, whereas in immunosuppressed 
patients, including human immunodeficiency virus-1 (HIV-1)-
infected and transplant patients, it remains a significant cause 
of morbidity and potentially life threatening complications (18). 
HCMV has a broad impact on immunity (16) and has recently 
been associated with the expansion of adaptive or memory-like 
NK-cell subsets (19, 20).
In the context of HIV infection, HCMV is a highly prevalent 
(21) and well-recognized opportunistic pathogen responsible 
for significant morbidity and mortality prior to the introduction 
of antiretroviral treatment (ART) (22, 23). However, despite the 
roll-out of effective ART, HCMV remains a significant cofac-
tor in HIV-1 disease progression (24–26), displaying a strong 
association with systemic inflammation (27, 28), cardiovas-
cular disease (29, 30), reduced immune resilience (31), and 
immune senescence (27). A recent report has highlighted the 
role of HCMV replication in intestinal barrier dysfunction in 
asymptomatic HIV-1 infection and contribution to persistent 
immune activation (32). It is thus highly relevant to increase 
our understanding of the complex inter-relationship between 
HCMV and HIV-1 and of the effects that it bears on the effector 
immune response. The recent identification of distinct NK-cell 
subsets with adaptive properties induced by HCMV has raised 
a number of intriguing questions, including the ability of other 
viruses to induce them and their physiological relevance in 
different disease settings. Here, we summarize findings on the 
molecular signature of HCMV-adapted NK  cells and discuss 
how NK-cell phenotypic and functional features described in 
HIV-1 infection could partly reflect the immunological finger-
print of HCMV.
FeATUReS OF CMv-ADAPTeD nK 
CeLLS—eMPHASiS On HCMv
Evidence from both murine and human studies has demon-
strated an important role for NK cells in antiviral defense against 
herpesviruses, in particular HCMV (33), reinforced by elaborate 
viral evasion strategies (34).
Although NK cells have been originally described to repre-
sent short-lived innate lymphocytes, they can exhibit persistent 
memory in response to infections. This is best exemplified by 
mouse CMV (MCMV) infection, where naive NK  cells that 
express Ly49H, recognizing the virally encoded glycoprotein 
m157, were reported to clonally expand and to subsequently 
contract forming a pool of long-lived memory cells (6). MCMV-
primed memory NK cells mount a robust response upon second-
ary challenge with enhanced interferon-γ (IFN-γ) secretion and 
cytotoxicity (6), but display reduced “bystander” functionality to 
heterologous infection suggesting the specialized nature of these 
cells (35).
Congruent with animal models, HCMV infection has been 
shown to induce an adaptive reconfiguration of the NK-cell 
compartment. Seminal work by Lopez-Botet’s group described 
a higher proportion of NK cells expressing the DAP-12 coupled 
NKG2C receptor in healthy individuals seropositive for HCMV 
(36, 37). These observations have been extended to hematopoietic 
stem cell transplantation (38, 39) and solid organ transplantation 
(40). Expansion of these subpopulations of NK  cells and their 
subsequent longevity resembled clonal expansion of adaptive 
immune cells. Expanded NKG2C+ NK cells display a differenti-
ated phenotype characterized by expression of CD57, increased 
expression of the inhibitory CD85j (38, 40), and a preferential 
oligoclonal pattern of inhibitory killer immunoglobulin receptors 
(KIRs) for self HLA-C1 and/or C2 allotypes (41, 42). In addition, 
they lack NKG2A, the inhibitory counterpart of NKG2C sharing 
specificity for HLA-E, and express lower levels of natural cyto-
toxicity receptors (NCR: NKp30 and NKp46) (36), CD161, CD7, 
and Siglec-7 (43–45) and have higher expression of CD2 involved 
in their activation (46, 47). Expression of other receptors such as 
NKG2D is maintained (36). The phenotypic hallmarks of adaptive 
NK cells are summarized in Figure 1. Of note, the magnitude of 
the HCMV imprint on NK-cell subsets varies within seropositive 
individuals (i.e., the NKG2Cbright phenotype is found in 50% of 
HCMV+ individuals) and the adaptive NKG2C+ compartment 
can persist in high frequencies for years (41). Subclinical or tissue 
specific reactivations of HCMV during latency may contribute 
to the maintenance of NK+NKG2C+ pool in addition to NKG2C 
copy number and age-related changes in NK-cell differentiation 
(48, 49). The exact ligand involved in recognition and the cellular 
mechanisms driving the expansion of NKG2C+ NK cells are yet 
to be elucidated. It remains unclear whether this is mediated 
through interaction with its cellular ligand HLA-E alone, HLA 
viral loaded peptide or an unknown ligand of host or viral origin 
(41, 50–52).
The large phenotypic heterogeneity of adaptive NK  cells 
extending beyond the NKG2C+ subset, is illustrated by the 
detection of NK-cell subsets sharing numerous attributes of 
adaptive NK  cells in individuals independent of NKG2C or in 
the absence of NKG2C (KLRC2-deficient individuals) and in 
transplant recipients of NKG2C null grafts (41, 47, 53). Strikingly, 
these HCMV-driven expansions encompass activating KIRs (53), 
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FiGURe 1 | The phenotypic, functional and molecular attributes of human cytomegalovirus (HCMV)-adapted natural killer (NK) cells. (A) As CD56dim NK cells go 
through the spectrum of differentiation they gradually lose expression of the inhibitory receptor NKG2A, natural cytotoxicity receptors and sequentially acquire more 
specific inhibitory receptors, such as inhibitory killer immunoglobulin receptors (KIRs) and CD85j. KIR acquisition is important in determining the functional fate of the 
NK cells. CD57 expression represents a terminal step in the differentiation process. Fully mature NK cells gain cytolytic ability and are efficient in mediating 
antibody-dependent cellular cytotoxicity (ADCC) (B) NK cells with adaptive features expanded in response to HCMV infection are distinct from conventional NK cells 
on the basis of expression of surface receptors, such as high expression of NKG2C, lower expression of the inhibitory Siglec-7, and down-regulation of the 
transcription factor promyelocytic leukemia zinc finger and key signaling molecules (FcεRI-γ, Syk, and EAT-2). Different combinations of expression patterns result in 
considerable heterogeneity among adaptive NK cells. Epigenetic diversification leads to altered target cell specificities and functional specialization that includes 
enhanced ADCC (increased IFN-γ and TNF-α against opsonized HCMV-infected targets) but reduced responsiveness to cytokine stimulation and reduced 
degranulation against autologous T cells. Red = inhibitory receptors; green = activating receptors.
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Further reports described a subset of human NK cells defi-
cient for the adaptor protein FcεRI-γ, which was strongly associ-
ated with HCMV seropositivity (54). FcεRI-γ− NK cells share a 
lot of the characteristics of adaptive NK cells, respond robustly 
to CD16 stimulation (55) and similar to NKG2C+ cells display 
more vigorous effector responses to HCMV-infected targets, 
but only in the presence of HCMV-specific antibodies (54, 56). 
NK cells lacking FcεRI-γ expand in response to HCMV-infected 
targets accentuated by the presence of anti-HCMV antibody, 
highlighting the role of specific humoral immunity in also 
favoring their preferential expansion (57–59). Interestingly, 
these cells also responded to herpes-simplex virus-1 (HSV-
1)-infected targets in the presence of HSV-1 plasma (54) 
demonstrating cross-protection to other viruses. The enhanced 
effector function of this subset was attributed to selective 
and more potent signaling through the CD3ζ chain, which 
has three immunoreceptor tyrosine-based activation motifs. 
Subsequently, CD2 has been identified as a key co-stimulatory 
receptor synergizing with CD16 to stimulate increased cytokine 
production in adaptive NK cells (47). Global epigenetic profil-
ing has identified commonalities between adaptive NK  cells 
and memory CD8 T cells (58, 60). These adaptive NK cells are 
marked by DNA methylation silencing of the transcription 
factor, promyelocytic leukemia zinc finger (PLZF), as well as 
stochastic down-regulation of several signaling molecules, such 
as Syk, EAT-2, and DAB-2 (58, 60). PLZF is known to interact 
with several target genes, including IL12RB2, IL18RAP, and 
KLRB1 (61), explaining the lack of responsiveness to IL12/
IL18 stimulation (58). However, in comparison to conventional 
NK  cells, adaptive NK  cells display augmented IFN-γ and 
TNF-α production when triggered via antibody-dependent 
cellular cytotoxicity (ADCC); the hypomethylated IFN-γ and 
tumor necrosis factor (TNF) regulatory regions in adaptive 
NK cells provide a mechanism for increased cytokine produc-
tion (58, 60). Interestingly, adaptive NK  cells display reduced 
degranulation toward activated autologous T cells (58), which 
may impact on the regulation of immune responses.
Taken together, these results suggest the heterogeneity and 
functional specialization of adaptive NK  cells in the immuno-
surveillance of infected cells and functional bias toward ADCC 
(Figure 1). Whereas the expansion of adaptive NK cells may serve 
as a strategy to control HCMV, during its life long interaction 
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with the host, it remains unclear whether other viral infections 
can induce adaptive properties in NK cells. Although potential 
cross-reactivity of adaptive NK cells could confer an advantage 
in the tumor setting such as reduced relapse risk in leukemia 
patients (62, 63), their role in the control of heterologous infec-
tions or post vaccination is less well defined (64, 65).
SKewinG AnD ADAPTATiOn OF nK 
CeLLS TO Hiv-1 inFeCTiOn: THe 
COnFOUnDinG eFFeCT OF HCMv
Accumulating data support an important role for NK cells in 
the control of HIV-1 infection and protection against disease 
acquisition (66–68). These stem from elegant genetic studies 
linking specific KIR/HLA combinations with HIV-1 outcome 
(66, 67), functional studies where protective KIR alleles are 
associated with enhanced NK-cell cytolytic function in  vitro 
(69) and evidence of KIR-facilitated immune pressure on 
HIV-1 to escape NK-cell recognition (70). However, chronic 
HIV-1 infection is known to alter NK-cell composition and 
effector function. This has been documented by a number of 
studies with often conflicting results, which can be attributed 
to a number of factors including the influence of immunogenet-
ics, disease state, and the cross-sectional nature of studies. The 
latter have not always adequately controlled for a number of 
confounding factors such as age, gender, ethnicity, and HCMV 
serostatus among HIV-1-infected and HIV-1-negative controls. 
Given the high prevalence of HCMV co-infection within HIV 
cohorts and the profound skewing and adaptation of NK cells 
to HCMV, this is an important variable to consider when inter-
preting findings.
HIV-1 viremia is associated with a significant and pathologi-
cal redistribution of the NK compartment with the emergence 
of an aberrant CD56−CD16+ NK-cell subset (71, 72). This rare 
population displays phenotypic perturbations, including down-
regulation of the activating NCRs, and features in common 
with mature CD56dim NK  cells (72, 73). It has been proposed 
to represent an activated subset generated from chronic target 
engagement with impaired function. Recent studies have 
demonstrated that a decreased expression of the c-lectin-type 
inhibitory receptor, Siglec-7, on NK  cells occurs early during 
HIV-1 infection and precedes the loss of CD56 (74). Expression 
of Siglec-7 is not affected in long-term non-progressors (LTNP), 
and ART leads to a progressive restoration of NK-cell subsets 
(74). Paralleling the observations in HIV-1 infection, HCMV 
reactivation in patients undergoing umbilical cord blood 
transplantation has been shown to induce the expansion of the 
CD56−/CD16+/Siglec-7− NK-cell subset (38). The expansion of 
hypofunctional CD56− NK cells following HCMV reactivation 
likely occurs when T-cell immunity is impaired and may also 
reflect the modulating effects of HCMV. It remains to be deter-
mined whether the CD56−/CD16+ subset represents a subgroup 
of NK cells with adaptive features that has become anergic fol-
lowing repeated stimulation.
A number of other studies have reported a variable degree 
of perturbations in the NK-cell repertoire consistent with a 
dichotomous effect of viremia, including down-regulation of 
activating NK-cell receptors and up-regulation of expression 
of inhibitory NK receptors (iNKRs) (75–77). Collectively, these 
changes have been described to contribute to defective NK-cell 
function described in HIV-1 infection (76, 77). Although the 
HCMV serostatus is not always considered in these studies, it is 
plausible that these changes are biased by HCMV co-infection 
and possible reactivation with increasing immunosuppression. 
Along these lines, the observed down-regulation of NCRs, 
stable expression of NKG2D, and higher levels of CD85j and 
skewing of inhibitory KIRs (although not consistently reported) 
bear phenotypic resemblance to NK-cell subsets with adaptive 
features described in HCMV infection. NK cells in HIV-1 infec-
tion exhibit a higher ratio of CD57+ to CD57− due to the loss 
of CD57− cells in comparison to healthy controls; however, this 
comparison may be confounded by the HCMV status of these 
individuals, which was not reported (78). A shift toward a more 
mature terminally differentiated NK-cell phenotype is none-
theless supported by a study of HIV-1 infected individuals on 
effective ART, demonstrating that HCMV accelerates age-related 
increases in CD57 expression (79).
The most convincing evidence of the impact of HCMV co-
infection on the NK-cell repertoire in HIV-1 infection comes 
from reports on NKG2C expression. Guma et  al. originally 
proposed that HCMV co-infection is responsible for the 
expansions of NKG2C+ NK cells encountered in HIV-1 infected 
individuals (80). These findings were further supported by 
additional studies when the HCMV serostatus was taken into 
consideration (81, 82). The dramatic expansion of NKG2C+ 
NK  cells in HIV-1 infected individuals was accompanied 
by a decrease in the expression of NKG2A leading to a low 
NKG2A/C+ NK-cell ratio; these changes were attributed to 
concomitant infection and/or HCMV reactivation rather than 
being a consequence of HIV-1 infection alone (82). A number 
of reports describe NKG2C+ NK-cell expansions in several 
acute and chronic viral infections, being systematically associ-
ated with HCMV co-infection (83–86). Although the relative 
increase in the proportions of NKG2C+ NK  cells between 
HIV-1-infected and HIV-1-uninfected HCMV seropositive 
individuals varies between studies and cohorts (80, 81), the 
data suggest that the impact of HCMV exposure is potentially 
greater in HIV-1 infection. It has been suggested by animal 
models that the differentiation of adaptive NK cells is driven 
by inflammation (87). Thus, it is plausible that adaptive NK-cell 
expansions may be inflated in HIV-1 infected individuals, as a 
result of lack of immune control, ongoing immune activation 
and higher infectious burdens, including HCMV. One could 
speculate that the size of the HCMV imprint represents a 
compensatory mechanism in antiviral defense especially when 
T-cell-mediated control is impaired (88). It remains uncertain 
whether HCMV reactivation occurs alongside acute infection 
or alternatively whether pre-existing HCMV primed NK-cell 
subsets expand in response to secondary viral infection alone. 
HIV-1 causes down-regulation of HLA-A, B while retaining 
HLA-E expression (89, 90), similar to HCMV maintaining/
stabilizing HLA-E expression (91, 92). Thus, a direct effect 
of HIV-1 on NKG2C+ NK-cell expansion is conceivable. The 
FiGURe 2 | Proposed model of the cumulative effect of human 
cytomegalovirus (HCMV) and ongoing immune activation on natural killer (NK) 
cells. Pre-existing HCMV-adapted NK cells expand during human 
immunodeficiency virus-1 infection to a variable degree depending on the 
tempo of HCMV reactivation, underlying level of immune activation, 
decreased T-cell-mediated control, and host genetics. HCMV co-infection 
accelerates NK-cell maturation and partly underlies the expansion of NK 
subsets with adaptive features in addition to the emergence of an aberrant 
CD56−CD16+ NK-cell subset. Whether these subsets become progressively 
dysregulated or exhausted remains to be determined.
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recently reported down-regulation of HLA-C by most primary 
HIV-1 clones (93) raises questions about the ability of HCMV 
expanded NKG2C+ NK  cells, preferentially expressing self-
HLA-C KIRs, to recognize “missing-self ” on HIV-infected 
targets compared to mature educated NK cells.
Open questions remain regarding not only the mechanism 
but also the clinical implications of such HCMV-NK-cell 
interaction in terms of protection against acquisition and 
HIV-1 disease progression. NKG2C deletions have been linked 
to a higher risk of contracting HIV-1, in addition to acceler-
ated disease progression and elevated pre-treatment viral load 
(94). Although these findings are interesting, this study did not 
report and correct for the influence of HCMV co-infection. 
One could speculate that the expansion of NKG2C+ NK cells in 
HCMV seropositive individuals may confer protection against 
primary HIV-1; this notion is however not supported by some 
older observations that prior infection with HCMV is associ-
ated with low CD4 count, progression to AIDS and increased 
mortality (95). It has been suggested that maturation leads to 
divergence and increased NK-cell receptor diversity was found 
to be associated with an increased risk of HIV-1 acquisition in 
a small cohort of high-risk women (96). Given that viral chal-
lenge may increase receptor diversity, further work is required 
to determine whether this represents reduced plasticity to new 
challenging pathogens or whether it is linked to other immune 
characteristics such as exhaustion. Recently, a subpopulation 
of PD1+ NK cells, mainly composed of fully mature NK cells, 
has been described in HCMV+ individuals (97). It would be 
of interest to assess whether NK  cells expanded in HCMV/
HIV-1 co-infection succumb to continuous stimulation and 
examine the factors that may contribute to the induction of PD1 
in this setting. PD1 signaling could therefore down-regulate 
not only T-cell-mediated responses but also innate responses, 
and this mechanism may be particularly prominent in HIV-1 
infection (98).
Conversely, a link between a mature NK-cell compartment 
(CD57+) and decreased levels of viral load and immune activa-
tion at the time of the primary HIV-1 infection has been reported. 
Those patients with a mature NK profile at inclusion showed a 
better early response to ART in comparison to patients with 
an immature NK profile (99). However, the HCMV serostatus 
of these individuals is not recorded and the status of NK  cells 
at the point of infection is not known. Whether mature CD57+ 
or NKG2C+CD57+ NK  cells represent adaptive NK  cells that 
contribute directly to better virus control during acute HIV-1 
infection and how their role evolves during chronic infection 
remain unclear.
In agreement with the findings in HCMV seropositive indi-
viduals, an NK-cell population that lacks FcεRI-γ expression and 
has superior ADCC activity has been identified in HIV-1 viremic 
individuals and shown to persist following virological suppres-
sion with ART (100, 101). This subset shares some phenotypic 
characteristics with adaptive NK cells induced by HCMV (100). 
Although this subset is associated with HCMV antibody levels in 
the general population, in HIV-1-infected individuals correlates 
with inflammatory markers (100). The long-term effects of expan-
sion of FcεRI-γ-deficient NK cells in HIV-1 infection needs to 
be further elucidated given a possible role in tumor surveillance. 
Nonetheless, the identification of a subset with enhanced ADCC 
activity in HIV-1 infection has potentially important implications 
for the design of vaccine strategies aimed at generating ADCC-
promoting antibody responses.
These collective data demonstrate that a number of the phe-
notypic NK-cell features described in HIV-1 bear the trademarks 
of HCMV infection (Figure 2). With increased definition of the 
assortment of NK-cell subsets with adaptive features driven by 
HCMV infection and the increased appreciation of HCMV in 
driving ongoing immune activation even during effective ART, 
it would be important to reassess the NK-cell repertoire com-
position, their response potential in different phases of infection 
and stimulus-dependent functional properties. A comprehen-
sive analysis of the transcriptional signatures and epigenetic 
modifications of NK cells in HIV-1 infection is lacking and worth 
exploring.
COnCLUDinG ReMARKS AnD FUTURe 
PeRSPeCTiveS
The potent effector function of NK  cells and the rapidity of 
NK-cell response have identified them as key areas for research. 
Recent reports about the diversity of NK-cell repertoire and abil-
ity to assume adaptive features in response to HCMV infection 
and even display memory-like responses to cytokines (102) and 
antigen-specific responses in primates (8) have opened up pros-
pects for the generation of new therapies. HCMV co-infection 
is highly prevalent in HIV-1 infected cohorts and remains an 
important cofactor in disease progression even in the era of ART. 
Both HIV-1 and HCMV as well as immune activation can further 
shape NK-cell responsiveness and differentiation. It is therefore 
important to capture the diversity of the NK-cell repertoire 
and identify potentially novel adaptive signatures of NK-cell 
subsets with preserved activation pathways. Whereas a number 
of questions remain regarding the epigenetic diversification, 
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development, and persistence of NK cells with adaptive proper-
ties, elucidating how clonal NK-cell populations can be directed 
or reshaped will critically inform our ability to harness NK cells 
toward a therapeutic goal.
AUTHOR COnTRiBUTiOnS
The author confirms being the sole contributor of this work and 
approved it for publication.
ACKnOwLeDGMenTS
My apologies to colleagues whose work could not be cited due to 
space limitations.
FUnDinG
This work was supported by an MRC grant MR/M008614/1 
awarded to DP.
ReFeRenCeS
1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. 
Innate or adaptive immunity? The example of natural killer cells. Science 
(2011) 331(6013):44–9. doi:10.1126/science.1198687 
2. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act 
as rheostats modulating antiviral T  cells. Nature (2011) 481(7381):394–8. 
doi:10.1038/nature10624 
3. Peppa D, Gill US, Reynolds G, Easom NJ, Pallett LJ, Schurich A, et  al. 
Up-regulation of a death receptor renders antiviral T  cells susceptible to 
NK  cell-mediated deletion. J Exp Med (2013) 210(1):99–114. doi:10.1084/
jem.20121172 
4. O’Leary JG, Goodarzi M, Drayton DL, von Andrian UH. T  cell- and 
B cell-independent adaptive immunity mediated by natural killer cells. Nat 
Immunol (2006) 7(5):507–16. doi:10.1038/ni1332 
5. Paust S, Gill HS, Wang BZ, Flynn MP, Moseman EA, Senman B, et al. Critical 
role for the chemokine receptor CXCR6 in NK cell-mediated antigen-spe-
cific memory of haptens and viruses. Nat Immunol (2010) 11(12):1127–35. 
doi:10.1038/ni.1953 
6. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. 
Nature (2009) 457(7229):557–61. doi:10.1038/nature07665 
7. O’Sullivan TE, Sun JC, Lanier LL. Natural killer cell memory. Immunity 
(2015) 43(4):634–45. doi:10.1016/j.immuni.2015.09.013 
8. Reeves RK, Li H, Jost S, Blass E, Li H, Schafer JL, et  al. Antigen-specific 
NK  cell memory in rhesus macaques. Nat Immunol (2015) 16(9):927–32. 
doi:10.1038/ni.3227 
9. Lanier LL. NK  cell recognition. Annu Rev Immunol (2005) 23:225–74. 
doi:10.1146/annurev.immunol.23.021704.115526 
10. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et  al. 
Activating receptors and coreceptors involved in human natural killer 
cell-mediated cytolysis. Annu Rev Immunol (2001) 19:197–223. doi:10.1146/
annurev.immunol.19.1.197 
11. Caligiuri MA. Human natural killer cells. Blood (2008) 112(3):461–9. 
doi:10.1182/blood-2007-09-077438 
12. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, 
Dogan OC, et al. Genetic and environmental determinants of human NK cell 
diversity revealed by mass cytometry. Sci Transl Med (2013) 5(208):208ra145. 
doi:10.1126/scitranslmed.3006702 
13. Manser AR, Weinhold S, Uhrberg M. Human KIR repertoires: shaped 
by genetic diversity and evolution. Immunol Rev (2015) 267(1):178–96. 
doi:10.1111/imr.12316 
14. Horowitz A, Djaoud Z, Nemat-Gorgani N, Blokhuis J, Hilton HG, Beziat 
V, et al. Class I HLA haplotypes form two schools that educate NK cells in 
different ways. Sci Immunol (2016) 1(3):eaag1672. doi:10.1126/sciimmunol.
aag1672 
15. Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, Christophides 
T, et  al. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural 
killer cells residing in human liver. Sci Rep (2016) 6:26157. doi:10.1038/ 
srep26157 
16. Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, et al. Variation 
in the human immune system is largely driven by non-heritable influences. 
Cell (2015) 160(1–2):37–47. doi:10.1016/j.cell.2014.12.020 
17. Roederer M, Quaye L, Mangino M, Beddall MH, Mahnke Y, Chattopadhyay 
P, et al. The genetic architecture of the human immune system: a bioresource 
for autoimmunity and disease pathogenesis. Cell (2015) 161(2):387–403. 
doi:10.1016/j.cell.2015.02.046 
18. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovi-
rus. J Pathol (2015) 235(2):288–97. doi:10.1002/path.4437 
19. Rolle A, Pollmann J, Cerwenka A. Memory of infections: an emerging role for 
natural killer cells. PLoS Pathog (2013) 9(9):e1003548. doi:10.1371/journal.
ppat.1003548 
20. Rolle A, Brodin P. Immune adaptation to environmental influence: the case 
of NK cells and HCMV. Trends Immunol (2016) 37(3):233–43. doi:10.1016/j.
it.2016.01.005 
21. Gianella S, Massanella M, Wertheim JO, Smith DM. The sordid affair between 
human herpesvirus and HIV. J Infect Dis (2015) 212(6):845–52. doi:10.1093/
infdis/jiv148 
22. Emery VC. Investigation of CMV disease in immunocompromised patients. 
J Clin Pathol (2001) 54(2):84–8. doi:10.1136/jcp.54.2.84 
23. Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus 
disease in the era of highly active antiretroviral therapy (HAART). J Clin 
Virol (2006) 37(1):1–9. doi:10.1016/j.jcv.2006.03.005 
24. Patel EU, Gianella S, Newell K, Tobian AA, Kirkpatrick AR, Nalugoda F, et al. 
Elevated cytomegalovirus IgG antibody levels are associated with HIV-1 
disease progression and immune activation. AIDS (2017) 31(6):807–13. 
doi:10.1097/QAD.0000000000001412 
25. Deayton JR, Prof Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD. 
Importance of cytomegalovirus viraemia in risk of disease progression and 
death in HIV-infected patients receiving highly active antiretroviral therapy. 
Lancet (2004) 363(9427):2116–21. doi:10.1016/S0140-6736(04)16500-8 
26. Adland E, Klenerman P, Goulder P, Matthews PC. Ongoing burden of disease 
and mortality from HIV/CMV coinfection in Africa in the antiretroviral 
therapy era. Front Microbiol (2015) 6:1016. doi:10.3389/fmicb.2015.01016 
27. Freeman ML, Lederman MM, Gianella S. Partners in crime: the role of CMV 
in immune dysregulation and clinical outcome during HIV infection. Curr 
HIV/AIDS Rep (2016) 13(1):10–9. doi:10.1007/s11904-016-0297-9 
28. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr 
HIV/AIDS Rep (2012) 9(2):139–47. doi:10.1007/s11904-012-0118-8 
29. Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, et al. 
Cytomegalovirus coinfection is associated with an increased risk of severe 
non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect 
Dis (2015) 211(2):178–86. doi:10.1093/infdis/jiu417 
30. Sacre K, Hunt PW, Hsue PY, Maidji E, Martin JN, Deeks SG, et al. A role for 
cytomegalovirus-specific CD4+CX3CR1+ T cells and cytomegalovirus-in-
duced T-cell immunopathology in HIV-associated atherosclerosis. AIDS 
(2012) 26(7):805–14. doi:10.1097/QAD.0b013e328351f780 
31. Barrett L, Stapleton SN, Fudge NJ, Grant MD. Immune resilience in 
HIV-infected individuals seronegative for cytomegalovirus. AIDS (2014) 
28(14):2045–9. doi:10.1097/QAD.0000000000000405 
32. Maidji E, Somsouk M, Rivera JM, Hunt PW, Stoddart CA. Replication of 
CMV in the gut of HIV-infected individuals and epithelial barrier dysfunc-
tion. PLoS Pathog (2017) 13(2):e1006202. doi:10.1371/journal.ppat.1006202 
33. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an 
adolescent without natural killer cells. N Engl J Med (1989) 320(26):1731–5. 
doi:10.1056/NEJM198906293202605 
34. Noriega V, Redmann V, Gardner T, Tortorella D. Diverse immune evasion 
strategies by human cytomegalovirus. Immunol Res (2012) 54(1–3):140–51. 
doi:10.1007/s12026-012-8304-8 
7Peppa HIV-1/HCMV Co-Infection and NK Cells
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1322
35. Min-Oo G, Lanier LL. Cytomegalovirus generates long-lived antigen-specific 
NK  cells with diminished bystander activation to heterologous infection. 
J Exp Med (2014) 211(13):2669–80. doi:10.1084/jem.20141172 
36. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet 
M. Imprint of human cytomegalovirus infection on the NK  cell receptor 
repertoire. Blood (2004) 104(12):3664–71. doi:10.1182/blood-2004-05-2058 
37. Guma M, Budt M, Saez A, Brckalo T, Hengel H, Angulo A, et al. Expansion 
of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected 
fibroblasts. Blood (2006) 107(9):3624–31. doi:10.1182/blood-2005-09-3682 
38. Della Chiesa M, Falco M, Podesta M, Locatelli F, Moretta L, Frassoni F, et al. 
Phenotypic and functional heterogeneity of human NK cells developing after 
umbilical cord blood transplantation: a role for human cytomegalovirus? 
Blood (2012) 119(2):399–410. doi:10.1182/blood-2011-08-372003 
39. Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et  al. 
Cytomegalovirus reactivation after allogeneic transplantation promotes a 
lasting increase in educated NKG2C+ natural killer cells with potent func-
tion. Blood (2012) 119(11):2665–74. doi:10.1182/blood-2011-10-386995 
40. Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. 
Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during 
acute human cytomegalovirus infection. Proc Natl Acad Sci U S A (2011) 
108(36):14725–32. doi:10.1073/pnas.1110900108 
41. Beziat V, Liu LL, Malmberg JA, Ivarsson MA, Sohlberg E, Bjorklund AT, 
et al. NK cell responses to cytomegalovirus infection lead to stable imprints 
in the human KIR repertoire and involve activating KIRs. Blood (2013) 
121(14):2678–88. doi:10.1182/blood-2012-10-459545 
42. Djaoud Z, David G, Bressollette C, Willem C, Rettman P, Gagne K, et  al. 
Amplified NKG2C+ NK  cells in cytomegalovirus (CMV) infection 
preferentially express killer cell Ig-like receptor 2DL: functional impact in 
controlling CMV-infected dendritic cells. J Immunol (2013) 191(5):2708–16. 
doi:10.4049/jimmunol.1301138 
43. Luetke-Eversloh M, Killig M, Romagnani C. Signatures of human NK cell 
development and terminal differentiation. Front Immunol (2013) 4:499. 
doi:10.3389/fimmu.2013.00499 
44. Muntasell A, Vilches C, Angulo A, Lopez-Botet M. Adaptive reconfiguration 
of the human NK-cell compartment in response to cytomegalovirus: a 
different perspective of the host-pathogen interaction. Eur J Immunol (2013) 
43(5):1133–41. doi:10.1002/eji.201243117 
45. Beziat V, Dalgard O, Asselah T, Halfon P, Bedossa P, Boudifa A, et al. CMV 
drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in 
chronic hepatitis patients. Eur J Immunol (2012) 42(2):447–57. doi:10.1002/
eji.201141826 
46. Rolle A, Halenius A, Ewen EM, Cerwenka A, Hengel H, Momburg F. 
CD2-CD58 interactions are pivotal for the activation and function of adap-
tive natural killer cells in human cytomegalovirus infection. Eur J Immunol 
(2016) 46(10):2420–5. doi:10.1002/eji.201646492 
47. Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA, et  al. 
Critical role of CD2 co-stimulation in adaptive natural killer cell responses 
revealed in NKG2C-deficient humans. Cell Rep (2016) 15(5):1088–99. 
doi:10.1016/j.celrep.2016.04.005 
48. Muntasell A, Lopez-Montanes M, Vera A, Heredia G, Romo N, Penafiel J, 
et al. NKG2C zygosity influences CD94/NKG2C receptor function and the 
NK-cell compartment redistribution in response to human cytomegalovirus. 
Eur J Immunol (2013) 43(12):3268–78. doi:10.1002/eji.201343773 
49. Goodier MR, White MJ, Darboe A, Nielsen CM, Goncalves A, Bottomley 
C, et al. Rapid NK cell differentiation in a population with near-universal 
human cytomegalovirus infection is attenuated by NKG2C deletions. Blood 
(2014) 124(14):2213–22. doi:10.1182/blood-2014-05-576124 
50. Rolle A, Pollmann J, Ewen EM, Le VT, Halenius A, Hengel H, et al. IL-12-
producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell 
expansion. J Clin Invest (2014) 124(12):5305–16. doi:10.1172/JCI77440 
51. Lauterbach N, Wieten L, Popeijus HE, Voorter CE, Tilanus MG. HLA-E 
regulates NKG2C+ natural killer cell function through presentation 
of a restricted peptide repertoire. Hum Immunol (2015) 76(8):578–86. 
doi:10.1016/j.humimm.2015.09.003 
52. Foley B, Cooley S, Verneris MR, Curtsinger J, Luo X, Waller EK, et  al. 
Human cytomegalovirus (CMV)-induced memory-like NKG2C(+) 
NK  cells are transplantable and expand in  vivo in response to recipient 
CMV antigen. J Immunol (2012) 189(10):5082–8. doi:10.4049/jimmunol. 
1201964 
53. Della Chiesa M, Falco M, Bertaina A, Muccio L, Alicata C, Frassoni F, 
et  al. Human cytomegalovirus infection promotes rapid maturation of 
NK cells expressing activating killer Ig-like receptor in patients transplanted 
with NKG2C-/- umbilical cord blood. J Immunol (2014) 192(4):1471–9. 
doi:10.4049/jimmunol.1302053 
54. Zhang T, Scott JM, Hwang I, Kim S. Cutting edge: antibody-dependent 
memory-like NK  cells distinguished by FcRgamma deficiency. J Immunol 
(2013) 190(4):1402–6. doi:10.4049/jimmunol.1203034 
55. Hwang I, Zhang T, Scott JM, Kim AR, Lee T, Kakarla T, et al. Identification 
of human NK cells that are deficient for signaling adaptor FcRgamma and 
specialized for antibody-dependent immune functions. Int Immunol (2012) 
24(12):793–802. doi:10.1093/intimm/dxs080 
56. Wu Z, Sinzger C, Frascaroli G, Reichel J, Bayer C, Wang L, et al. Human cyto-
megalovirus-induced NKG2C(hi) CD57(hi) natural killer cells are effectors 
dependent on humoral antiviral immunity. J Virol (2013) 87(13):7717–25. 
doi:10.1128/JVI.01096-13 
57. Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, et al. Epigenetic modifi-
cation and antibody-dependent expansion of memory-like NK cells in human 
cytomegalovirus-infected individuals. Immunity (2015) 42(3):431–42. 
doi:10.1016/j.immuni.2015.02.013 
58. Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, et  al. 
Cytomegalovirus infection drives adaptive epigenetic diversification of 
NK  cells with altered signaling and effector function. Immunity (2015) 
42(3):443–56. doi:10.1016/j.immuni.2015.02.008 
59. Costa-Garcia M, Vera A, Moraru M, Vilches C, Lopez-Botet M, Muntasell A. 
Antibody-mediated response of NKG2Cbright NK cells against human cyto-
megalovirus. J Immunol (2015) 194(6):2715–24. doi:10.4049/jimmunol.1402281 
60. Luetke-Eversloh M, Hammer Q, Durek P, Nordstrom K, Gasparoni G, Pink 
M, et al. Human cytomegalovirus drives epigenetic imprinting of the IFNG 
locus in NKG2Chi natural killer cells. PLoS Pathog (2014) 10(10):e1004441. 
doi:10.1371/journal.ppat.1004441 
61. Gleimer M, von Boehmer H, Kreslavsky T. PLZF controls the expression of 
a limited number of genes essential for NKT cell function. Front Immunol 
(2012) 3:374. doi:10.3389/fimmu.2012.00374 
62. Green ML, Leisenring WM, Xie H, Walter RB, Mielcarek M, Sandmaier BM, 
et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for 
early protection in acute myeloid leukemia. Blood (2013) 122(7):1316–24. 
doi:10.1182/blood-2013-02-487074 
63. Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, et  al. 
CD56dimCD57+NKG2C+ NK  cell expansion is associated with reduced 
leukemia relapse after reduced intensity HCT. Leukemia (2016) 30(2):456–63. 
doi:10.1038/leu.2015.260 
64. Nielsen CM, White MJ, Bottomley C, Lusa C, Rodriguez-Galan A, Turner SE, 
et al. Impaired NK cell responses to pertussis and H1N1 influenza vaccine 
antigens in human cytomegalovirus-infected individuals. J Immunol (2015) 
194(10):4657–67. doi:10.4049/jimmunol.1403080 
65. Darboe A, Danso E, Clarke E, Umesi A, Touray E, Wegmuller R, et  al. 
Enhancement of cytokine-driven NK cell IFN-gamma production after vac-
cination of HCMV infected Africans. Eur J Immunol (2017) 47(6):1040–50. 
doi:10.1002/eji.201746974 
66. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic 
interaction between KIR3DS1 and HLA-B delays the progression to AIDS. 
Nat Genet (2002) 31(4):429–34. doi:10.1038/ng934 
67. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate part-
nership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 
39(6):733–40. doi:10.1038/ng2035 
68. Boulet S, Kleyman M, Kim JY, Kamya P, Sharafi S, Simic N, et al. A combined 
genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated 
with a reduced risk of HIV infection. AIDS (2008) 22(12):1487–91. 
doi:10.1097/QAD.0b013e3282ffde7e 
69. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, 
et al. Differential natural killer cell-mediated inhibition of HIV-1 replication 
based on distinct KIR/HLA subtypes. J Exp Med (2007) 204(12):3027–36. 
doi:10.1084/jem.20070695 
70. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, 
et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 
476(7358):96–100. doi:10.1038/nature10237 
71. Alter G, Teigen N, Davis BT, Addo MM, Suscovich TJ, Waring MT, et  al. 
Sequential deregulation of NK  cell subset distribution and function 
8Peppa HIV-1/HCMV Co-Infection and NK Cells
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1322
starting in acute HIV-1 infection. Blood (2005) 106(10):3366–9. doi:10.1182/
blood-2005-03-1100 
72. Mavilio D, Lombardo G, Benjamin J, Kim D, Follman D, Marcenaro E, 
et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly 
dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc 
Natl Acad Sci U S A (2005) 102(8):2886–91. doi:10.1073/pnas.0409872102 
73. Milush JM, Lopez-Verges S, York VA, Deeks SG, Martin JN, Hecht FM, et al. 
CD56negCD16(+) NK  cells are activated mature NK  cells with impaired 
effector function during HIV-1 infection. Retrovirology (2013) 10:158. 
doi:10.1186/1742-4690-10-158 
74. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, et al. 
The decreased expression of Siglec-7 represents an early marker of dysfunc-
tional natural killer-cell subsets associated with high levels of HIV-1 viremia. 
Blood (2009) 114(18):3822–30. doi:10.1182/blood-2009-06-226332 
75. Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, et al. 
Natural killer cells in HIV-1 infection: dichotomous effects of viremia on 
inhibitory and activating receptors and their functional correlates. Proc Natl 
Acad Sci U S A (2003) 100(25):15011–6. doi:10.1073/pnas.2336091100 
76. Fauci AS, Mavilio D, Kottilil S. NK  cells in HIV infection: paradigm for 
protection or targets for ambush. Nat Rev Immunol (2005) 5(11):835–43. 
doi:10.1038/nri1760 
77. Ansari AW, Ahmad F, Meyer-Olson D, Kamarulzaman A, Jacobs R, Schmidt 
RE. Natural killer cell heterogeneity: cellular dysfunction and significance 
in HIV-1 immuno-pathogenesis. Cell Mol Life Sci (2015) 72(16):3037–49. 
doi:10.1007/s00018-015-1911-5 
78. Hong HS, Eberhard JM, Keudel P, Bollmann BA, Ballmaier M, Bhatnagar N, 
et al. HIV infection is associated with a preferential decline in less-differen-
tiated CD56dim CD16+ NK cells. J Virol (2010) 84(2):1183–8. doi:10.1128/
JVI.01675-09 
79. Affandi JS, Montgomery J, Brunt SJ, Nolan D, Price P. The immunological 
footprint of CMV in HIV-1 patients stable on long-term ART. Immun Ageing 
(2015) 12:14. doi:10.1186/s12979-015-0041-0 
80. Guma M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, et al. Human cyto-
megalovirus infection is associated with increased proportions of NK cells 
that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. 
J Infect Dis (2006) 194(1):38–41. doi:10.1086/504719 
81. Mela CM, Goodier MR. The contribution of cytomegalovirus to changes in 
NK cell receptor expression in HIV-1-infected individuals. J Infect Dis (2007) 
195(1):158–9; author reply 9–60. doi:10.1086/509811 
82. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, et al. 
Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer 
cells in patients with human cytomegalovirus co-infection. AIDS (2010) 
24(1):27–34. doi:10.1097/QAD.0b013e3283328d1f 
83. Bjorkstrom NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, et al. 
Rapid expansion and long-term persistence of elevated NK  cell numbers 
in humans infected with hantavirus. J Exp Med (2011) 208(1):13–21. 
doi:10.1084/jem.20100762 
84. Petitdemange C, Becquart P, Wauquier N, Beziat V, Debre P, Leroy EM, et al. 
Unconventional repertoire profile is imprinted during acute chikungunya 
infection for natural killer cells polarization toward cytotoxicity. PLoS Pathog 
(2011) 7(9):e1002268. doi:10.1371/journal.ppat.1002268 
85. Saghafian-Hedengren S, Sohlberg E, Theorell J, Carvalho-Queiroz C, Nagy 
N, Persson JO, et  al. Epstein-Barr virus coinfection in children boosts 
cytomegalovirus-induced differentiation of natural killer cells. J Virol (2013) 
87(24):13446–55. doi:10.1128/JVI.02382-13 
86. Malone DFG, Lunemann S, Hengst J, Ljunggren HG, Manns MP, Sandberg 
JK, et al. Cytomegalovirus-driven adaptive-like natural killer cell expansions 
are unaffected by concurrent chronic hepatitis virus infections. Front 
Immunol (2017) 8:525. doi:10.3389/fimmu.2017.00525 
87. Sun JC, Madera S, Bezman NA, Beilke JN, Kaplan MH, Lanier LL. 
Proinflammatory cytokine signaling required for the generation of 
natural killer cell memory. J Exp Med (2012) 209(5):947–54. doi:10.1084/
jem.20111760 
88. Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E. 
Human NK cells can control CMV infection in the absence of T cells. Blood 
(2008) 112(3):914–5. doi:10.1182/blood-2008-05-157354 
89. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, 
et al. The selective downregulation of class I major histocompatibility com-
plex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 
(1999) 10(6):661–71. doi:10.1016/S1074-7613(00)80065-5 
90. Nattermann J, Nischalke HD, Hofmeister V, Kupfer B, Ahlenstiel G, 
Feldmann G, et  al. HIV-1 infection leads to increased HLA-E expression 
resulting in impaired function of natural killer cells. Antivir Ther (2005) 
10(1):95–107. 
91. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, et al. 
Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced 
by human cytomegalovirus gpUL40. Science (2000) 287(5455):1031. 
doi:10.1126/science.287.5455.1031 
92. Djaoud Z, Riou R, Gavlovsky PJ, Mehlal S, Bressollette C, Gerard N, et al. 
Cytomegalovirus-infected primary endothelial cells trigger NKG2C+ nat-
ural killer cells. J Innate Immun (2016) 8(4):374–85. doi:10.1159/000445320 
93. Apps R, Del Prete GQ, Chatterjee P, Lara A, Brumme ZL, Brockman MA, 
et al. HIV-1 Vpu mediates HLA-C downregulation. Cell Host Microbe (2016) 
19(5):686–95. doi:10.1016/j.chom.2016.04.005 
94. Thomas R, Low HZ, Kniesch K, Jacobs R, Schmidt RE, Witte T. NKG2C 
deletion is a risk factor of HIV infection. AIDS Res Hum Retroviruses (2012) 
28(8):844–51. doi:10.1089/AID.2011.0253 
95. Sabin CA, Phillips AN, Lee CA, Janossy G, Emery V, Griffiths PD. The effect of 
CMV infection on progression of human immunodeficiency virus disease is a 
cohort of haemophilic men followed for up to 13 years from seroconversion. 
Epidemiol Infect (1995) 114(2):361–72. doi:10.1017/S095026880005799X 
96. Strauss-Albee DM, Fukuyama J, Liang EC, Yao Y, Jarrell JA, Drake AL, 
et al. Human NK cell repertoire diversity reflects immune experience and 
correlates with viral susceptibility. Sci Transl Med (2015) 7(297):297ra115. 
doi:10.1126/scitranslmed.aac5722 
97. Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, et  al. 
Identification of a subset of human natural killer cells expressing high 
levels of programmed death 1: a phenotypic and functional characterization. 
J Allergy Clin Immunol (2017) 139(1):335–46.e3. doi:10.1016/j.jaci.2016. 
04.025 
98. Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier 
MR. PD-1 expression on natural killer cells and CD8(+) T  cells during 
chronic HIV-1 infection. Viral Immunol (2012) 25(4):329–32. doi:10.1089/
vim.2011.0096 
99. Gondois-Rey F, Cheret A, Mallet F, Bidaut G, Granjeaud S, Lecuroux C, 
et al. A mature NK profile at the time of HIV primary infection is associated 
with an early response to cART. Front Immunol (2017) 8:54. doi:10.3389/
fimmu.2017.00054 
100. Zhou J, Amran FS, Kramski M, Angelovich TA, Elliott J, Hearps AC, et al. 
An NK  cell population lacking FcRgamma is expanded in chronically 
infected HIV patients. J Immunol (2015) 194(10):4688–97. doi:10.4049/
jimmunol.1402448 
101. Hearps AC, Agius PA, Zhou J, Brunt S, Chachage M, Angelovich TA, et al. 
Persistence of activated and adaptive-like NK  cells in HIV+ individuals 
despite 2 years of suppressive combination antiretroviral therapy. Front 
Immunol (2017) 8:731. doi:10.3389/fimmu.2017.00731 
102. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. 
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A 
(2009) 106(6):1915–9. doi:10.1073/pnas.0813192106 
Conflict of Interest Statement: The author declares that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The reviewer AH and handling editor declared their shared affiliation.
Copyright © 2017 Peppa. This is an open-access article distributed under the terms 
of the Creative Commons Attribution License (CC BY). The use, distribution or 
reproduction in other forums is permitted, provided the original author(s) or licensor 
are credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is permitted 
which does not comply with these terms.
